Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)

NCT07054242 is registered in ClinicalTrials.gov with Yantai Yuhuangding Hospital as lead sponsor.

NCT NCT07054242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07054242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
Lead sponsor
Yantai Yuhuangding Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 30, 2025
Completion date
June 30, 2028
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant therapy, stage ii to iii (t1cn1-2 or t2-4n0-2) tnbc breast cancer